David S.
- Country
- Czechia
- Department
- 1502: Klinika detske hematologie a onkologie
Research Overview
- (20290) A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
- Phase 1/2 Evaluation of Cobolimab and Dostarlimab in Pediatric and Young Adult Patients with Newly Diagnosed and Relapsed/Refractory Solid Tumors
- Evaluation of Lenvatinib Efficacy and Safety in Pediatric Patients with Relapsed or Refractory High-Grade Glioma and Other Solid Tumors
Data & Insights
Has run more than one trial at 84 of 198 partner sites.
Specializations
Pediatric Oncology
The investigator specializes in treating various forms of pediatric solid tumors, with particular focus on rare and complex cases. Their expertise extends to managing high-grade gliomas and rhabdomyosarcoma.
- Advanced Solid Tumors
- Neuroblastoma
- Ependymoma
Their work encompasses innovative therapeutic approaches for children and young adults with challenging tumor presentations.
Neurological Oncology
Focused on treating complex central nervous system tumors, including specialized care for atypical teratoid/rhabdoid tumors (ATRT) and various grades of brain malignancies.
- Intracranial Ependymoma
- Spinal Tumors
- Medulloblastoma
The investigator employs targeted therapeutic strategies for neurological cancers across different age groups.
Immunological Conditions
Expertise in treating chronic spontaneous urticaria and implementing novel therapeutic approaches for immune-mediated conditions.
- Autoimmune Disorders
- Inflammatory Conditions
- Targeted Immunotherapy
Their practice incorporates advanced treatment modalities for managing chronic immunological disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.